切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2025, Vol. 14 ›› Issue (02) : 203 -208. doi: 10.3877/cma.j.issn.2095-3232.2025028

专家论坛

胆囊癌肿瘤微环境与系统治疗
陈博滔1, 胡宽1, 毛先海1,()   
  1. 1. 410005 长沙,湖南省人民医院(湖南师范大学附属第一医院)肝胆外科
  • 收稿日期:2024-12-26 出版日期:2025-04-10
  • 通信作者: 毛先海
  • 基金资助:
    湖南省自然科学基金(2023JJ40371)

Tumor microenvironment and systematic treatment of gallbladder cancer

Botao Chen1, Kuan Hu1, Xianhai Mao1,()   

  1. 1. Department of Hepatobiliary Surgery, Hunan Provincial People’s Hospital (the First Affiliated Hospital of Hunan Normal University), Changsha 410005, China
  • Received:2024-12-26 Published:2025-04-10
  • Corresponding author: Xianhai Mao
引用本文:

陈博滔, 胡宽, 毛先海. 胆囊癌肿瘤微环境与系统治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 203-208.

Botao Chen, Kuan Hu, Xianhai Mao. Tumor microenvironment and systematic treatment of gallbladder cancer[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 203-208.

胆囊癌是消化系统最常见恶性肿瘤之一,具有临床症状隐匿、侵袭性强且易转移等特点,致死率高。近年来,许多临床研究从胆囊癌的新辅助治疗、辅助治疗、转化治疗等方面进行了探索,为改善胆囊癌患者的预后做出巨大努力。本文拟对胆囊癌的发病机制及肿瘤微环境进行概述,并对最近5 年胆囊癌系统治疗的临床研究新进展进行分析和总结。

Gallbladder cancer is one of the most common malignant tumors in digestive system, which is characterized with hidden clinical symptoms, high invasion and metastasis and high mortality.Recent clinical studies have explored the neoadjuvant therapy, adjuvant therapy and translational therapy of gallbladder cancer,making tremendous efforts to improve the clinical prognosis of patients with gallbladder cancer.In this article,the pathogenesis and tumor microenvironment of gallbladder cancer were reviewed, and novel progress in clinical research of systematic treatment for gallbladder cancer in recent 5 years was analyzed and summarized.

[1]
中国抗癌协会.中国恶性肿瘤整合诊治指南: 胆囊癌[J].肿瘤, 2022,42(3): 188-202.DOI: 10.3781/j.issn.1000-7431.2022.2112-0938.Association CA.Chinese guidelines for integrated diagnosis and treatment of malignant tumors: gallbladder cancer[J].Tumor, 2022,42(3): 188-202.DOI: 10.3781/j.issn.1000-7431.2022.2112-0938.
[2]
中华医学会外科学分会胆道外科学组, 中国医师协会外科医师分会胆道外科专业委员会.胆囊癌诊断和治疗指南(2019版)[J].中华外科杂志, 2020, 58(4): 243-251.DOI: 10.3760/cma.j.cn112139-20200106-00014.Branch of Biliary Surgery of Chinese Surgery Society of Chinese Medical Association, Chinese Medical Doctor Association in Chinese Committee of Biliary Surgeons.Guideline for the diagnosis and treatment of gallbladder carcinoma (2019 edition)[J].Chin J Surg,2020, 58(4): 243-251.DOI: 10.3760/cma.j.cn112139-20200106-00014.
[3]
Benson AB, D’Angelica MI, Abrams T, et al.NCCN guidelines®insights: biliary tract cancers, version 2.2023[J].J Natl Compr Canc Netw, 2023, 21(7): 694-704.DOI: 10.6004/jnccn.2023.0035.
[4]
Rebholz C, Krawczyk M, Lammert F.Genetics of gallstone disease[J].Eur J Clin Invest, 2018, 48(7): e12935.DOI: 10.1111/eci.12935.
[5]
Di Ciaula A, Garruti G, Frühbeck G, et al.The role of diet in the pathogenesis of cholesterol gallstones[J].Curr Med Chem, 2019,26(19): 3620-3638.DOI: 10.2174/0929867324666170530080636.
[6]
Yang P, Javle M, Pang F, et al.Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients[J].Hepatobiliary Surg Nutr, 2019, 8(6): 604-614.DOI: 10.21037/hbsn.2019.04.11.
[7]
Roa J, García P, Kapoor VK, et al.Gallbladder cancer[J].Nat Rev Dis Primers, 2022, 8(1): 69.DOI: 10.1038/s41572-022-00398-y.
[8]
Doherty G, Manktelow M, Skelly B, et al.The need for standardizing diagnosis, treatment and clinical care of cholecystitis and biliary colic in gallbladder disease[J].Medicina, 2022, 58(3): 388.DOI: 10.3390/medicina58030388.
[9]
Lammert F, Gurusamy K, Ko CW, et al.Gallstones[J].Nat Rev Dis Primers, 2016, 2: 16024.DOI: 10.1038/nrdp.2016.24.
[10]
Fukumura Y, Rong L, Maimaitiaili Y, et al.Precursor lesions of gallbladder carcinoma: disease concept, pathology, and genetics[J].Diagnostics, 2022, 12(2): 341.DOI: 10.3390/diagnostics12020341.
[11]
Iyer P, Barreto SG, Sahoo B, et al.Non-typhoidal Salmonella DNA traces in gallbladder cancer[J].Infect Agent Cancer, 2016, 11: 12.DOI: 10.1186/s13027-016-0057-x.
[12]
Hemminki K, Försti A, Hemminki O, et al.Long-term incidence and survival trends in cancer of the gallbladder and extrahepatic bile ducts in Denmark, Finland, Norway and Sweden with etiological implications related to Thorotrast[J].Int J Cancer, 2022, 151(2): 200-208.DOI: 10.1002/ijc.33980.
[13]
Muraki T, Pehlivanoglu B, Memis B, et al.Pancreatobiliary maljunction-associated gallbladder cancer is as common in the west, shows distinct clinicopathologic characteristics and offers an invaluable model for anatomy-induced reflux-associated physiochemical carcinogenesis[J].Ann Surg, 2022, 276(1): e32-e39.DOI:10.1097/SLA.0000000000004482.
[14]
Abdel-Wahab R, Yap TA, Madison R, et al.Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer[J].Sci Rep, 2020, 10(1): 22087.DOI: 10.1038/s41598-020-77939-6.
[15]
Ebata N, Fujita M, Sasagawa S, et al.Molecular classification and tumor microenvironment characterization of gallbladder cancer by comprehensive genomic and transcriptomic analysis[J].Cancers,2021, 13(4): 733.DOI: 10.3390/cancers13040733.
[16]
Javle M, Rashid A, Churi C, et al.Molecular characterization of gallbladder cancer using somatic mutation profiling[J].Hum Pathol,2014, 45(4): 701-708.DOI: 10.1016/j.humpath.2013.11.001.
[17]
Roessler S, Edeline J, Schirmacher P, et al.Integrative genomics highlights opportunities for innovative therapies targeting the tumor microenvironment in gallbladder cancer[J].J Hepatol, 2021, 74(5):1018-1020.DOI: 10.1016/j.jhep.2020.12.024.
[18]
Nepal C, Zhu B, O’Rourke CJ, et al.Integrative molecular characterisation of gallbladder cancer reveals micro-environmentassociated subtypes[J].J Hepatol, 2021, 74(5): 1132-1144.DOI:10.1016/j.jhep.2020.11.033.
[19]
Zhang Y, Zuo C, Liu L, et al.Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer[J].J Hepatol, 2021, 75(5): 1128-1141.DOI: 10.1016/j.jhep.2021.06.023.
[20]
Chen P, Wang Y, Li J, et al.Diversity and intratumoral heterogeneity in human gallbladder cancer progression revealed by single-cell RNA sequencing[J].Clin Transl Med, 2021, 11(6): e462.DOI: 10.1002/ctm2.462.
[21]
CSCO 胆道肿瘤专家委员会.CSCO胆道系统肿瘤诊断治疗专家共识(2019年版)[J].临床肿瘤学杂志, 2019, 24(9): 828-838.CSCO Committee of Experts on Biliary Tumors.Expert consensus on diagnosis and treatment of CSCO biliary systerm tumors(2019 edition)[J].Chin Clin Oncol, 2019, 24(9): 828-838.
[22]
Saluja SS, Nekarakanti PK, Mishra PK, et al.Prospective randomized controlled trial comparing adjuvant chemotherapy vs.No chemotherapy for patients with carcinoma of gallbladder undergoing curative resection[J].J Gastrointest Surg, 2022, 26(2): 398-407.DOI:10.1007/s11605-021-05143-6.
[23]
Seita K, Ebata T, Mizuno T, et al.Phase 2 trial of adjuvant chemotherapy with S-1 for node-positive biliary tract cancer (N-SOG 09)[J].Ann Surg Oncol, 2020, 27(7): 2348-2356.DOI: 10.1245/s10434-020-08355-3.
[24]
Nakachi K, Ikeda M, Konishi M, et al.Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT):a multicentre, open-label, randomised, controlled, phase 3 trial[J].Lancet, 2023, 401(10372): 195-203.DOI: 10.1016/S0140-6736(22)02038-4.
[25]
Sharma A, Mohanti BK, Chaudhary SP, et al.Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: results of a phaseⅢrandomised controlled trial[J].Eur J Cancer, 2019, 123: 162-170.DOI: 10.1016/j.ejca.2019.10.004.
[26]
Roa I, de Toro G, Schalper K, et al.Overexpression of the HER2/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer[J].Gastrointest Cancer Res, 2014, 7(2): 42-48.
[27]
Lee CK, Chon HJ, Cheon J, et al.Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)[J].Lancet Gastroenterol Hepatol, 2023,8(1): 56-65.DOI: 10.1016/S2468-1253(22)00335-1.
[28]
Javle M, Borad MJ, Azad NS, et al.Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre,open-label, phase 2a, multiple basket study[J].Lancet Oncol, 2021,22(9): 1290-1300.DOI: 10.1016/S1470-2045(21)00336-3.
[29]
Harding JJ, Fan J, Oh DY, et al.Zanidatamab for HER2-amplified,unresectable, locally advanced or metastatic biliary tract cancer(HERIZON-BTC-01): a multicentre, single-arm, phase 2b study[J].Lancet Oncol, 2023, 24(7): 772-782.DOI: 10.1016/S1470-2045(23)00242-5.
[30]
Demols A, Borbath I, Van den Eynde M, et al.Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind,phaseⅡtrial[J].Ann Oncol, 2020, 31(9): 1169-1177.DOI: 10.1016/j.annonc.2020.05.018.
[31]
Ikeda M, Ioka T, Fukutomi A, et al.Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine[J].Cancer Sci, 2018, 109(1): 215-224.DOI: 10.1111/cas.13438.
[32]
Subbiah V, Iannotti NO, Gutierrez M, et al.FIGHT-101, a first-inhuman study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies[J].Ann Oncol, 2022, 33(5): 522-533.DOI: 10.1016/j.annonc.2022.02.001.
[33]
Tan ES, Cao B, Kim J, et al.Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers[J].Cancer, 2021, 127(8): 1293-1300.DOI: 10.1002/cncr.33364.
[34]
Klein O, Kee D, Nagrial A, et al.Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial[J].JAMA Oncol, 2020, 6(9): 1405-1409.DOI: 10.1001/jamaoncol.2020.2814.
[35]
Ueno M, Ikeda M, Morizane C, et al.Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised,multicentre, open-label, phase 1 study[J].Lancet Gastroenterol Hepatol, 2019, 4(8): 611-621.DOI: 10.1016/S2468-1253(19)30086-X.
[36]
Oh DY, He AR, Bouattour M, et al.Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study[J].Lancet Gastroenterol Hepatol,2024,9(8):694-704.DOI: 10.1016/S2468-1253(24)00095-5.
[37]
Kelley RK, Ueno M, Yoo C, et al.Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966):a randomised, double-blind, placebo-controlled, phase 3 trial[J].Lancet, 2023, 401(10391): 1853-1865.DOI: 10.1016/S0140-6736(23)00727-4.
[38]
Guo Y, Feng K, Liu Y, et al.Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers[J].Clin Cancer Res, 2018, 24(6): 1277-1286.DOI: 10.1158/1078-0432.CCR-17-0432.
[39]
闫甲,刘双池,王政宇.胆囊癌肿瘤标志物的研究和应用进展[J].中华普通外科学文献(电子版),2023,17(5):391-394.DOI: 10.3877/cma.j.issn.1674-0793.2023.05.015.Yan J, Liu SC, Wang ZY.Progress in the reasearch and application of tumor markers for gallbladder cancer[J/OL].Chin Arch Gen Surg(Electron Ed), 2023, 17(5): 391-394.DOI: 10.3877/cma.j.issn.1674-0793.2023.05.015.
[40]
Rimini M, Fornaro L, Lonardi S, et al.Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data[J].Liver Int, 2023, 43(8): 1803-1812.DOI:10.1111/liv.15641.
[1] 姚宏伟, 孙丽婷. 腹腔镜中低位直肠癌新辅助放化疗联合免疫治疗后根治性保肛术[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 132-132.
[2] 张忠涛, 高加勒, 姚宏伟. 新辅助放化疗联合免疫治疗局部进展期直肠癌的现状与前景[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 119-122.
[3] 姚宏伟, 孙丽婷, 吴偲, 舒文龙, 高加勒, 杨正阳, 吴国聪, 张忠涛. 新辅助放化疗联合免疫治疗局部进展期直肠癌的探索与实践[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 123-127.
[4] 王乾宇, 杜峻峰, 李世拥. 新辅助放化疗联合免疫治疗局部进展期直肠癌的突破与挑战[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 128-131.
[5] 何友新, 韩林荟, 杨贺庆. 新辅助化疗分别联合保乳术和改良根治术治疗Ⅱ、Ⅲ期乳腺癌的应用效果[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 184-187.
[6] 吴楚营, 叶凯. 不同部位胃肠道间质瘤的腹腔镜手术策略[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 224-227.
[7] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[8] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[9] 朱洪浩, 范新祥. 广东省医学会泌尿外科疑难病例多学科会诊(第18期)——女性尿道癌[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 120-124.
[10] 刘青光, 耿智敏, 张东, 李起. 微创胆囊癌根治术的现状与思考[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 158-166.
[11] 丁志文, 赵一鸣, 王鲁. 肝内胆管癌手术与综合治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 187-196.
[12] 黄忠晶, 张丽东, 伍子奕, 艾军华. 不可切除肝细胞癌的转化治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 41-45.
[13] 孙志鹏, 束斌, 王良, 黄鑫, 王鹏飞, 李广欣, 王小娟, 黎功, 杨世忠. 放疗联合靶向免疫新辅助治疗肝内胆管细胞癌的安全性与疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 92-96.
[14] 沈小芳, 赵娜, 李克佳, 肖跃飞. 膜性肾病的靶抗原发现及靶向治疗研究进展[J/OL]. 中华肾病研究电子杂志, 2025, 14(01): 53-56.
[15] 王闪闪, 赵海涛. 胆道癌转化手术策略[J/OL]. 中华消化病与影像杂志(电子版), 2025, 15(01): 1-5.
阅读次数
全文


摘要